Article
Statin use is not associated with improved progression free survival in cetuximab treated KRAS mutant metastatic colorectal cancer patients: results from the CAIRO2 study.
PloS one - 1 Jan 2014
Krens Lisanne L, Simkens Lieke H J, Baas Jara M, Koomen Els R, Gelderblom Hans, Punt Cornelis J A, Guchelaar Henk-Jan
Abstract excerpt
Statins may inhibit the expression of the mutant KRAS phenotype by preventing the prenylation and thus the activation of the KRAS protein. This study was aimed at retrospectively evaluating the effect of statin use on outcome in KRAS mutant metastatic colorectal cancer patients (mCRC) treated with cetuximab. Treatment data were obtained from patients who were treated with capecitabine, oxaliplatin bevacizumab ±...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.